Segall Bryant & Hamill, LLC Editas Medicine, Inc. Transaction History

Segall Bryant & Hamill, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$26.55 - $40.57 $187,389 - $286,343	-7,058 Closed	0 $0
Q2 2021 Aug 12, 2021	SELL	$31.29 - $56.64 $4.65 Million - $8.42 Million	-148,681 Reduced 95.47%	7,058 $399,000
Q1 2021 May 13, 2021	SELL	$39.71 - $90.58 $2,382 - $5,434	-60 Reduced 0.04%	155,739 $6.54 Million
Q4 2020 Feb 12, 2021	SELL	$27.07 - $84.35 $2.7 Million - $8.41 Million	-99,750 Reduced 39.03%	155,799 $10.9 Million
Q3 2020 Nov 13, 2020	BUY	$28.06 - $37.16 $324,064 - $429,160	11,549 Added 4.73%	255,549 $7.17 Million
Q2 2020 Aug 14, 2020	SELL	$18.5 - $34.34 $102,675 - $190,587	-5,550 Reduced 2.22%	244,000 $7.22 Million
Q1 2020 May 14, 2020	SELL	$14.88 - $32.78 $58,032 - $127,842	-3,900 Reduced 1.54%	249,550 $4.95 Million
Q4 2019 Feb 11, 2020	SELL	$19.49 - $32.63 $73,087 - $122,362	-3,750 Reduced 1.46%	253,450 $7.5 Million
Q3 2019 Nov 12, 2019	SELL	$22.49 - $26.81 $304,739 - $363,275	-13,550 Reduced 5.0%	257,200 $5.85 Million
Q2 2019 Aug 14, 2019	SELL	$20.48 - $27.76 $4,096 - $5,552	-200 Reduced 0.07%	270,750 $0
Q1 2019 May 15, 2019	BUY	$19.43 - $26.41 $5.26 Million - $7.16 Million	270,950 New	270,950 $0

249

56.9M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $96.9M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Segall Bryant & Hamill, LLC, based on Form 13F filings with the SEC.

Stay updated on Segall Bryant & Hamill, LLC with notifications on news.